Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA

Abstract Background Biologics have revolutionized the management of psoriasis, but response to treatment varies. Loss of treatment efficacy may occur over time, requiring treatment switching or escalation. Claims data on persistence may be informative of real-world treatment outcome. This analysis d...

Full description

Bibliographic Details
Main Authors: Timothy Fitzgerald, Maryia Zhdanava, Dominic Pilon, Aditi Shah, Annalise Hilts, Patrick Lefebvre, Steven R. Feldman
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-03-01
Series:Dermatology and Therapy
Subjects:
Biologics
Guselkumab
Persistence
Psoriasis
Remission
Treatment discontinuation
Online Access:https://doi.org/10.1007/s13555-023-00910-6

Internet

https://doi.org/10.1007/s13555-023-00910-6

Similar Items